Critical Diagnostics

Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above.